VC  MDA Venture Philanthropy

     Office Locations:

c/o MDA National Headquarters
3300 E. Sunrise Drive
Tucson, AZ 85718
Phone: 520-615-6700



  • Early
  • Seed



  • Life Sciences & Healthcare



    MDA Venture Philanthropy (MVP) is the Muscular Dystrophy Association's drug development program, which operates within MDA's Translational Research program. MVP is exclusively focused on funding the discovery and clinical application of treatments and cures for neuromuscular diseases. MVP seeks to utilize scientific and business best practices to drive the market for therapeutic development in the following target areas: Amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease); Duchenne muscular dystrophy; Spinal muscular atrophy; and other neuromuscular diseases (Friedreich's ataxia, myotonic muscular dystrophy, limb-girdle muscular dystrophy, etc.). MVP evaluates and makes targeted investments in for-profit and not-for-profit companies and academics developing therapeutics for neuromuscular diseases. MDA Venture Philanthropy (MVP) does not provide traditional grants, but rather makes targeted investments in drug development for neuromuscular disease. Projects will be milestone-driven, contract-mediated and a return on investment will be negotiated. MVP utilizes a professional diligence process and is committed to a 16-week turnaround on investment decisions.

    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Growth Stage
    (also called Mid-stage)
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B

    Investment Team:

    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription.
    Jane Larkindale Ph.D. Director of Translational Research


    Portfolio companies include:

      Acceleron Pharma
        web link

      Akashi Therapeutics
        web link

      ALS Biopharma
        web link

        web link

      ARMGO Pharma
        web link

      Catabasis Pharmaceuticals
        web link

        web link

      Reveragen Biopharma
        web link

      Summit Plc
        web link

      Tivorsan Pharmaceuticals
        web link

      Valerion Therapeutics
        web link


    Recent News: